CHARLOTTES WEB HLDGS (CWBHF) Stock Price, News & Analysis

Charlotte's Web Holdings, Inc. (CWBHF) is a botanical wellness innovation company in the medicinal and botanical manufacturing industry. The company describes itself as a market leader in hemp extract wellness and hemp-derived CBD wellness, with products built around whole-plant hemp extracts and other plant-based ingredients. Charlotte's Web is a Certified B Corporation headquartered in Louisville, Colorado, and its shares trade on the Toronto Stock Exchange under the symbol CWEB and are quoted in U.S. dollars on the OTC under the symbol CWBHF.

According to company disclosures, Charlotte's Web focuses on hemp extract wellness that includes whole-plant full-spectrum CBD extracts, broad-spectrum CBD, and cannabinoid isolates. Its hemp extracts have naturally occurring botanical compounds such as cannabidiol (CBD), CBN, CBC, CBG, THC, terpenes, flavonoids, and other plant-derived compounds. This positions the company within the broader cannabinoid wellness and botanical supplements space, serving consumers seeking plant-based options for areas such as sleep, calming, exercise recovery, and general wellness.

Business model and product categories

Charlotte's Web describes its business as substantially vertically integrated. The company states that it maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance. This approach supports its positioning in regulated and health-focused channels, including distribution to retailers and healthcare practitioners across the U.S.A., as well as direct-to-consumer sales through online channels.

The company reports multiple product categories within its hemp extract and botanical wellness portfolio, including:

• CBD oil tinctures (liquid products)
• CBD gummies for sleep, calming, exercise recovery, and immunity
• CBN gummies
• CBG gummies and CBG Focus & Attention gummies
• Hemp-derived THC microdose gummies and Brightside hemp-derived THC gummies
• Functional mushroom gummies for areas such as Focus, Stress Support, Energy, Muscle Recovery, and Quiet Sleep
• CBD capsules and soft gels
• CBD topical creams and lotions
• CBD pet products for dogs

Within these categories, Charlotte's Web highlights specific focus areas such as sleep support, calming and stress support, exercise recovery, cognitive focus and attention, and general wellness. The company has expanded into hemp-derived THC microdose gummies and a Brightside line of fast-acting hemp-derived THC gummies, which are marketed as dietary supplements and are not intended for sale to persons under the age of 21.

Sleep and relaxation focus

Recent company communications emphasize sleep and relaxation as key growth categories. Charlotte's Web has launched Quiet Sleep Mushroom Gummies, a melatonin-free and cannabinoid-free formula that uses reishi mushroom fruiting bodies, chamomile flower extract, and magnesium citrate to support calm, relaxation, and quality sleep. The company also introduced Knockout hemp THC sleep gummies under the Brightside brand, combining hemp-derived THC and CBN in a gummy format designed to support both falling asleep and staying asleep, using a rapid-onset delivery technology.

These launches build on the company's existing sleep portfolio, which includes CBN Stay Sleep Gummies and other CBD gummies formulated for sleep. The company reports that sleep remains one of the top wellness priorities for consumers and positions its sleep-related offerings as plant-based alternatives to conventional options.

Functional mushrooms and botanical diversification

Beyond cannabinoids, Charlotte's Web has expanded into functional mushroom gummies, with formulations for Focus, Stress Support, Energy, and Muscle Recovery. These products feature ingredients such as Lion's Mane, Reishi, Cordyceps, and Turkey Tail, and are described as part of a broader botanical wellness ecosystem that extends beyond hemp. The company also highlights Quiet Sleep Mushroom Gummies as an example of a cannabinoid-free, mushroom-based sleep support product.

This diversification into functional mushrooms and nootropic-oriented products, such as CBG Focus & Attention Gummies, reflects the company's stated strategy to broaden its presence in adjacent wellness categories while leveraging its experience in botanical formulations and quality standards.

Medical channel and scientific focus

Charlotte's Web emphasizes a medical and science-based orientation in several disclosures. The company has announced the development and launch of a Scientific Advisory Board to guide research and development, shape clinical initiatives, and help translate botanical science into patient-centered solutions. The Scientific Advisory Board is described as advising on product formulations, practitioner education, and engagement, and supporting the creation of Continuing Medical Education (CME) content for healthcare professionals.

The company references a long-standing relationship with Realm of Caring, a nonprofit focused on cannabinoid therapy guidance and research coordination. Charlotte's Web notes that its products have been studied by leading institutions and that it integrates real-world evidence, patient-reported outcomes, and clinical insights into its research and development process.

In addition, Charlotte's Web participates in a Medicare and Medicaid Innovation (CMMI) pilot program that aims to expand access to CBD for senior oncology patients through healthcare insurance coverage. Under this program, the company will offer a set of products to address oncology patient needs via a secure online healthcare portal, as part of its medical channel business.

Partnerships and pharmaceutical pathway exposure

Charlotte's Web is a collaborator in DeFloria, Inc., an FDA Phase 2 clinical-stage botanical pharmaceutical company. DeFloria was formed by AJNA BioSciences PBC and Charlotte's Web Holdings, Inc., with a subsidiary of British American Tobacco plc as lead investor. DeFloria is developing AJA001 oral solution, a full-spectrum hemp-based investigational botanical drug for irritability associated with autism spectrum disorder, under the FDA botanical drug pathway. Charlotte's Web retains exclusive manufacturing rights for commercial supply of this candidate, which the company identifies as a potential long-term revenue opportunity.

The company also notes institutional support from British American Tobacco, including board representation pursuant to an investor rights agreement. This relationship is cited in connection with strategic support and governance expertise.

Distribution and channels

Charlotte's Web reports that its products are distributed to retailers and healthcare practitioners throughout the U.S.A. The company also highlights an omnichannel strategy that includes direct-to-consumer online sales and marketplace presence on platforms such as Amazon, Walmart.com, TikTok Shop, and Faire. It has described a restructuring of its B2B retail operations, emphasizing higher-margin distributor relationships, medical channels, and practitioner-focused offerings, while reducing lower-margin direct retail distribution.

The company has also internalized production of certain gummy products, including Brightside hemp-derived THC gummies, and is evaluating additional in-house manufacturing transitions. It states that this vertical integration supports quality control, innovation speed, and cost efficiencies.

Regulatory and advocacy context

Charlotte's Web frequently comments on the evolving regulatory landscape for hemp-derived products in the United States. The company participates in industry coalitions and advocacy efforts related to federal regulation of CBD and hemp extracts. It has noted federal legislative developments, state-level restrictions, and policy discussions around THC content limits in hemp-derived products. Charlotte's Web positions itself as engaged with bipartisan Congressional supporters, consumer advocacy groups, and industry coalitions to promote science-based, balanced regulation that distinguishes non-intoxicating hemp wellness products from high-potency synthetic cannabinoids.

The company is also associated with ONE HEMP, an industry coalition focused on advancing CBD as a dietary supplement through bipartisan legislation. Charlotte's Web's Chief Scientific Officer is identified as a member of ONE HEMP, which advocates for science-based regulation and standardized industry benchmarks.

Corporate structure and listing

Charlotte's Web Holdings, Inc. is incorporated in British Columbia, as reflected in its SEC filings. The company files reports such as Forms 10-Q and 8-K with the U.S. Securities and Exchange Commission and is identified with Commission File Number 000-56364. Its principal executive offices are located in Louisville, Colorado. Shares trade on the Toronto Stock Exchange under the symbol CWEB and are quoted on the OTC in the United States under the symbol CWBHF.

FAQs about Charlotte's Web Holdings, Inc. (CWBHF)

• What does Charlotte's Web Holdings, Inc. do?
  Charlotte's Web Holdings, Inc. is a botanical wellness innovation company focused on hemp extract wellness and hemp-derived CBD wellness products. It develops and sells products such as CBD oil tinctures, gummies, capsules, topicals, functional mushroom gummies, and CBD pet products for dogs.
• What industry is Charlotte's Web in?
  The company operates in the medicinal and botanical manufacturing space and describes itself as a market leader in hemp extract wellness and hemp-derived CBD wellness.
• Where is Charlotte's Web headquartered?
  Charlotte's Web states that it is headquartered in Louisville, Colorado, and is incorporated in British Columbia.
• On which exchanges does Charlotte's Web stock trade?
  Shares of Charlotte's Web trade on the Toronto Stock Exchange under the symbol CWEB and are quoted in U.S. dollars on the OTC under the symbol CWBHF.
• What types of products does Charlotte's Web offer?
  According to company disclosures, product categories include CBD oil tinctures, CBD gummies for sleep, calming, exercise recovery, and immunity, CBN gummies, CBG gummies, hemp-derived THC microdose gummies, Brightside hemp-derived THC gummies, functional mushroom gummies, CBD capsules and soft gels, CBD topical creams and lotions, and CBD pet products for dogs.
• How does Charlotte's Web describe its approach to quality?
  The company states that it operates a substantially vertically integrated business model and maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance.
• Does Charlotte's Web work with healthcare practitioners?
  Yes. Charlotte's Web reports that its products are distributed to healthcare practitioners throughout the U.S.A. and that it is developing a medical channel strategy, including practitioner education, Continuing Medical Education content, and participation in a Medicare and Medicaid Innovation pilot program for senior oncology patients.
• What is the Brightside line?
  Brightside is described as a line of fast-acting hemp-derived THC gummies from Charlotte's Web, with formulations such as Unwind, Focus, Recover, and Knockout. These gummies use a rapid-onset delivery technology and combine hemp-derived THC with other cannabinoids for targeted effects.
• What is Charlotte's Web's involvement with DeFloria, Inc.?
  DeFloria, Inc. is an FDA Phase 2 clinical-stage botanical pharmaceutical company formed by AJNA BioSciences PBC and Charlotte's Web Holdings, Inc., with a subsidiary of British American Tobacco plc as lead investor. DeFloria is developing AJA001 oral solution for irritability associated with autism spectrum disorder, and Charlotte's Web retains exclusive manufacturing rights for commercial supply.
• How is Charlotte's Web involved in industry regulation and advocacy?
  The company reports active engagement with industry coalitions and policymakers to shape federal and state regulation of hemp-derived products. It participates in efforts to establish clear regulatory pathways for CBD and is associated with ONE HEMP, an industry coalition focused on advancing CBD as a dietary supplement through bipartisan legislation.